Search

You searched for "screening"

2414 results found
Experimental Eye Research cover image.

HtrA1 enhances cell senescence

1 December 2013 | | EYE - Vitreo-Retinal
A genetic basis for age-related macular degeneration (AMD) has been greatly advanced in recent years. The role of identified pathways such as complement factor H in AMD has been widely investigated. However, the effect of other gene variants identified by...
Strabismus journal front cover image.

Hess vs. Harms vs. PCT measurements

1 June 2022 | | EYE - Paediatrics, EYE - Strabismus
This study aimed to compare the results of the different tests in 36 strabismus patients and 18 healthy controls aged 6-81 years. Tests included alternate prism cover test, Hess screen and Harms screen. Because of glasses restrictions with the Harms...

Belfast briefing: Retina Day roundup from the RCOphth 2024 Annual Congress

2 August 2024 | | EYE - General
Belfast hosted this year’s Royal College of Ophthalmologists’ (RCOphth) Annual Congress, a meeting dedicated to sharing advances, knowledge and clinical practice points in ophthalmic care. This article summarises selected talks by medical and surgical retina specialists during the Retina Subspecialty...

When the chatbot gets it wrong: Navigating AI-generated health misinformation in ophthalmology

20 August 2026 | | EYE - General
Patients are beginning to turn to large language model chatbots for healthcare information. As clinicians, we are not only required to know when they are wrong, but why they are wrong – and what we can do about it. Recently,...

Dolby’s Sound of a Masterpiece: Hear what Da Vinci's Mona Lisa and Monet's Water-Lily Pond sound like

9 April 2025 | RNIB, immersive experience, blindness, partially sighted, art, Dolby Laboratories, patient stories
Dolby Laboratories and Royal National Institute of Blind People (RNIB) have reimagined the world’s most famous artwork masterpieces - from Da Vinci’s Mona Lisa to David Hockney’s A Bigger Splash - to create an immersive soundtrack, in state-of-the-art Dolby Atmos...

High score

4 August 2025 | | EYE - General
Louie: “Allow me to present Pac-Man. Now, who is going to be the lucky pup who gets to play the first game? Iggy! You’re a somewhat compulsive personality. Step forward. Now… you see there’s the maze.” Iggy: “Uh-huh” Louie: “All...

OP-ED: How and why local healthcare providers can expand their services

17 March 2023
Staffing shortages, financial constraints, and an ongoing rise in demand: none of these factors remove the need for high-quality healthcare, yet combined they threaten its realisation.

The Global Vision Database

1 December 2015 | | EYE - General
The overall goal of the Global Vision Database (GVD) [1] is to develop and deploy new and improved evidence on the prevalence of blindness and vision impairment (VI) globally. It is a repository which allows us to assess the causes...

Outcomes at 100 weeks from the LEAVO study of intravitreal anti-VEGF therapies for macular oedema secondary to central retinal vein occlusion

23 May 2019 |
Royal College of Ophthalmologists Annual Congress 2019, Glasgow - First presented and discussed on Monday 20 May 2019, with a further presentation of results during Retina Subspecialty Day on Thursday 23 May 2019. Among patients with macular oedema secondary to...

Clear sight is ‘revelation’ for Yaxley resident following ‘life-changing’ surgery

9 December 2022
Retiree Steve Low has rekindled his love for photography.

Treatment for cause of sudden sight loss now available through the NHS in England

24 September 2025 | LHON, NICE, vision Loss, mitochondrial disease, NHS England
The National Institute for Health and Care Excellence (NICE) has approved a treatment for Leber Hereditary Optic Neuropathy (LHON), called Idebenone (Raxone), in those aged 12 and above who are affected by the condition. LHON is a rare mitochondrial genetic...

NICE approves treatment for cause of sudden sight loss

15 October 2025 | genetics, neuro-ophthalmology, drugs, new treatments, mitochondrial
The National Institute for Health and Care Excellence (NICE) has approved a treatment for Leber Hereditary Optic Neuropathy (LHON), called Idebenone (Raxone), in those aged 12 and above who are affected by the condition. LHON is a rare mitochondrial genetic...